Tokai Pharmaceuticals (NVUS) Getting Somewhat Critical Media Coverage, Accern Reports
News headlines about Tokai Pharmaceuticals (NASDAQ:NVUS) have been trending somewhat negative this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Tokai Pharmaceuticals earned a coverage optimism score of 0.00 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.4318078519138 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Separately, Zacks Investment Research raised shares of Tokai Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th.
Shares of Tokai Pharmaceuticals (NASDAQ NVUS) opened at 4.45 on Thursday. The company has a 50-day moving average of $4.13 and a 200-day moving average of $5.60. Tokai Pharmaceuticals has a 1-year low of $3.42 and a 1-year high of $18.83. The company’s market cap is $30.90 million.
TRADEMARK VIOLATION WARNING: “Tokai Pharmaceuticals (NVUS) Getting Somewhat Critical Media Coverage, Accern Reports” was reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2017/09/14/tokai-pharmaceuticals-nvus-getting-somewhat-critical-media-coverage-accern-reports.html.
About Tokai Pharmaceuticals
Novus Therapeutics, Inc, formerly Tokai Pharmaceuticals, Inc, is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities.
Receive News & Ratings for Tokai Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tokai Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.